SGLT2 抑制剂治疗的 2 型糖尿病患者血糖正常的糖尿病酮症酸中毒的临床和生化特征及危险因素分析：4.5 年 72 例回顾性研究。
Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
机构信息
Department of Internal Medicine, Mouscron Hospital Center, Avenue de Fécamp 49, 7700, Mouscron, Belgium; Pole of Cardiovascular Research, Institute of Experimental and Clinical Research, Catholic University of Louvain, 1200, Brussels, Belgium.
Department of Internal Medicine, Mouscron Hospital Center, Avenue de Fécamp 49, 7700, Mouscron, Belgium; Department of Diabetology, Mouscron Hospital Centre, Avenue de Fécamp 49, 7700, Mouscron, Belgium.
出版信息
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102275. doi: 10.1016/j.dsx.2021.102275. Epub 2021 Sep 15.
BACKGROUND AND AIMS
To study euglycemic diabetic ketoacidosis (euDKA) outcomes associated with sodium-glucose co-transporter 2 inhibitors (SGLT2is) METHODS: Review of 72 euDKA cases in T2DM between September 2015 and January 2020 (PUBMED).
RESULTS
euDKA could occur at any time during SGLT2is treatment, with nausea, abdominal pain and vomiting as main symptoms. Hyperglycemia did not correlate with pH and β-hydroxybutyrates. Low pH and high β-hydroxybutyrates were significantly associated with euDKA. In biguanides users, acidosis was unrelated to lactic acidosis. euDKA occurred during fasting, surgery, acute infection, insulin deprivation (endogenous or exogenous).
CONCLUSIONS
These data support avoidance of euDKA risk states in SGLT2i users.
背景和目的
研究与钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2is）相关的血糖正常的糖尿病酮症酸中毒（euDKA）结局。
方法
回顾 2015 年 9 月至 2020 年 1 月期间 T2DM 中 72 例 euDKA 病例（PUBMED）。
结果
euDKA 可在 SGLT2is 治疗期间的任何时间发生，主要症状为恶心、腹痛和呕吐。高血糖与 pH 值和β-羟丁酸无相关性。低 pH 值和高β-羟丁酸与 euDKA 显著相关。在二甲双胍使用者中，酸中毒与乳酸酸中毒无关。euDKA 发生于禁食、手术、急性感染、胰岛素缺乏（内源性或外源性）期间。
结论
这些数据支持避免 SGLT2i 使用者出现 euDKA 风险状态。
Zotero 插件